Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Babcock shares jump as annual profit, revenue guidance lifted

(Sharecast News) - Shares in Babcock spiked on Thursday as the UK defence contractor upgraded full-year expectations on the back of double-digit organic growth in its nuclear operations and strong growth in the marine division. The company said it now expects revenue in the year to March 31 to come in at £4.9bn compared with forecasts of £4.51bn - £4.78bn and underlying operating profit to beat the top end of a £327.1m - £339.7m range. Babcock stock jumped 7.5% on the news.

Babcock on Thursday said its first-half strong trading performance had continued throughout the third quarter of the year, and the preliminary view of performance in January was also "encouraging".

"In nuclear, growth is driven by increased new build and decommissioning work in civil nuclear, as well as increased submarine support activity and higher than originally expected infrastructure revenues. In marine, the growth is enhanced by higher LGE volumes as well as the ramp-up of the (UK military satellite) Skynet programme," the company said on Thursday.

Broker Shore Capital maintained its 'buy' rating on Babcock shares, noting that "positive secular trends around defence spending and nuclear investment and decommissioning" would create strong value in Babcock's fundamental multiples, "especially as the balance sheet continues to strengthen".

"We hope to see further upgrade opportunities emerge as we enter Babcock's new financial year with more granular and firmer guidance," they added.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.